164 related articles for article (PubMed ID: 30594747)
1. PD-L1 expression and association with malignant behavior in pheochromocytomas/paragangliomas.
Guo D; Zhao X; Wang A; Xie Q; Xu X; Sun J
Hum Pathol; 2019 Apr; 86():155-162. PubMed ID: 30594747
[TBL] [Abstract][Full Text] [Related]
2. Pheochromocytoma/Paraganglioma: A Poster Child for Cancer Metabolism.
Tevosian SG; Ghayee HK
J Clin Endocrinol Metab; 2018 May; 103(5):1779-1789. PubMed ID: 29409060
[TBL] [Abstract][Full Text] [Related]
3. Histological features, Ki-67 and Bcl-2 immunohistochemical expression and their correlation with the aggressiveness of pheochromocytomas.
Jovanovic R; Kostadinova-Kunovska S; Bogoeva B; Spasevska L; Petrusevska G
Prilozi; 2012; 33(2):23-40. PubMed ID: 23425867
[TBL] [Abstract][Full Text] [Related]
4. Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors.
Sadow PM; Rumilla KM; Erickson LA; Lloyd RV
Endocr Pathol; 2008; 19(2):97-103. PubMed ID: 18461287
[TBL] [Abstract][Full Text] [Related]
5. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
[TBL] [Abstract][Full Text] [Related]
6. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors.
Kimura N; Watanabe T; Noshiro T; Shizawa S; Miura Y
Endocr Pathol; 2005; 16(1):23-32. PubMed ID: 16000843
[TBL] [Abstract][Full Text] [Related]
7. Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas.
Mete O; Pakbaz S; Lerario AM; Giordano TJ; Asa SL
Am J Surg Pathol; 2021 Sep; 45(9):1264-1273. PubMed ID: 33826547
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of stem cell markers in pheochromocytomas/paragangliomas is associated with SDHx mutations.
Oudijk L; Neuhofer CM; Lichtenauer UD; Papathomas TG; Korpershoek E; Stoop H; Oosterhuis JW; Smid M; Restuccia DF; Robledo M; de Cubas AA; Mannelli M; Gimenez-Roqueplo AP; Dinjens WN; Beuschlein F; de Krijger RR
Eur J Endocrinol; 2015 Jul; 173(1):43-52. PubMed ID: 25916394
[TBL] [Abstract][Full Text] [Related]
9. Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques.
Kumaki N; Kajiwara H; Kameyama K; DeLellis RA; Asa SL; Osamura RY; Takami H
Endocr Pathol; 2002; 13(2):149-56. PubMed ID: 12165664
[TBL] [Abstract][Full Text] [Related]
10. Mastermind Like Transcriptional Coactivator 3 (MAML3) Drives Neuroendocrine Tumor Progression.
Alzofon N; Koc K; Panwell K; Pozdeyev N; Marshall CB; Albuja-Cruz M; Raeburn CD; Nathanson KL; Cohen DL; Wierman ME; Kiseljak-Vassiliades K; Fishbein L
Mol Cancer Res; 2021 Sep; 19(9):1476-1485. PubMed ID: 33986121
[TBL] [Abstract][Full Text] [Related]
11. Morphologic Clues to Succinate Dehydrogenase (SDH) Deficiency in Pheochromocytomas and Paragangliomas.
Turchini J; Gill AJ
Am J Surg Pathol; 2020 Mar; 44(3):422-424. PubMed ID: 31789631
[No Abstract] [Full Text] [Related]
12. Growth factors and cytokines in paragangliomas and pheochromocytomas, with special reference to sustentacular cells.
Kontogeorgos G; Scheithauer BW; Kovacs K; Horvath E; Melmed S
Endocr Pathol; 2002; 13(3):197-206. PubMed ID: 12446918
[TBL] [Abstract][Full Text] [Related]
13. Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas.
Leijon H; Remes S; Hagström J; Louhimo J; Mäenpää H; Schalin-Jäntti C; Miettinen M; Haglund C; Arola J
Hum Pathol; 2019 Apr; 86():66-75. PubMed ID: 30529752
[TBL] [Abstract][Full Text] [Related]
14. Vascular pattern analysis for the prediction of clinical behaviour in pheochromocytomas and paragangliomas.
Oudijk L; van Nederveen F; Badoual C; Tissier F; Tischler AS; Smid M; Gaal J; Lepoutre-Lussey C; Gimenez-Roqueplo AP; Dinjens WN; Korpershoek E; de Krijger R; Favier J
PLoS One; 2015; 10(3):e0121361. PubMed ID: 25794004
[TBL] [Abstract][Full Text] [Related]
15. Pheochromocytomas and paragangliomas in humans and dogs.
Galac S; Korpershoek E
Vet Comp Oncol; 2017 Dec; 15(4):1158-1170. PubMed ID: 28120550
[TBL] [Abstract][Full Text] [Related]
16. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies.
Santarpia L; Habra MA; Jiménez C
Horm Metab Res; 2009 Sep; 41(9):680-6. PubMed ID: 19343618
[TBL] [Abstract][Full Text] [Related]
17. The mTORC1 Complex Is Significantly Overactivated in SDHX-Mutated Paragangliomas.
Oudijk L; Papathomas T; de Krijger R; Korpershoek E; Gimenez-Roqueplo AP; Favier J; Canu L; Mannelli M; Rapa I; Currás-Freixes M; Robledo M; Smid M; Papotti M; Volante M
Neuroendocrinology; 2017; 105(4):384-393. PubMed ID: 28122379
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of the insulin-like growth factor 1 receptor (IGF-1R) is associated with malignancy in familial pheochromocytomas and paragangliomas.
Fernandez MC; Martin A; Venara M; Calcagno Mde L; Sansó G; Quintana S; Chemes HE; Barontini M; Pennisi PA
Clin Endocrinol (Oxf); 2013 Nov; 79(5):623-30. PubMed ID: 23506534
[TBL] [Abstract][Full Text] [Related]
19. Expression of somatostatin receptors, dopamine D₂ receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas.
Saveanu A; Muresan M; De Micco C; Taieb D; Germanetti AL; Sebag F; Henry JF; Brunaud L; Enjalbert A; Weryha G; Barlier A
Endocr Relat Cancer; 2011 Apr; 18(2):287-300. PubMed ID: 21335363
[TBL] [Abstract][Full Text] [Related]
20. N-Glycomic Profiling of Pheochromocytomas and Paragangliomas Separates Metastatic and Nonmetastatic Disease.
Leijon H; Kaprio T; Heiskanen A; Satomaa T; Hiltunen JO; Miettinen MM; Arola J; Haglund C
J Clin Endocrinol Metab; 2017 Nov; 102(11):3990-4000. PubMed ID: 28938401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]